Amigal

Amicus' 'Transformative' Changes Look More Like Big Step Backward
Amicus' 'Transformative' Changes Look More Like Big Step Backward
TheStreet.com
Amicus Therapeutics
GSK
Sanofi
Biomarin
Callidus Biopharma
Amigal
Flag link:
Amicus Delays U.S. Approval Filing for Fabry Disease Drug
Amicus Delays U.S. Approval Filing for Fabry Disease Drug
TheStreet.com
Fabry's disease
Amicus
GSK
Amigal
Flag link:
Biotech Stock Mailbag: 2013 Clinical Trials Calendar
Biotech Stock Mailbag: 2013 Clinical Trials Calendar
TheStreet.com
Zerenex
Xoma
Vical
Takeda
sovaprevir
Soluble Ferric Pyrophosphate
Rockwell Medical
Orexigen
MM-398
Merrimack Pharmaceuticals
MannKind
Keryx
GTx
GSK
gevokizumab
enobosarm
Coronado Biosciences
Contrave
CNDO-201
clinical trials
ChemoCentryx
CCX140
Biodel
BIOD-123
Amigal
Amicus Therapeutics
Alnylam
ALN-TTR02
Allovectin
Afrezza
Achillion
ACH-3102
Flag link:
A Legit Reason To Give Amicus' Fabry Drug Another Chance
A Legit Reason To Give Amicus' Fabry Drug Another Chance
TheStreet.com
Amicus
Fabry's disease
Amigal
Flag link:
Amicus Fabry Drug Fails Pivotal Trial
Amicus Fabry Drug Fails Pivotal Trial
TheStreet.com
Amicus
Fabry's disease
Amigal
GSK
Flag link:
Amicus Soon To Release New Phase III Data
Amicus Soon To Release New Phase III Data
Seeking Alpha
Amicus
AT1001
Amigal
Migalastat HCl
Fabry's disease
Flag link:
Amicus: Bullish Options Trade Into Clinical Trial Catalysts
Amicus: Bullish Options Trade Into Clinical Trial Catalysts
TheStreet.com
Amicus
clinical trials
Amigal
Flag link:
Amicus Therapeutics Poised For Rebound Into December Phase III Results
Amicus Therapeutics Poised For Rebound Into December Phase III Results
Seeking Alpha
Amicus Therapeutics
GSK
Amigal
Flag link:
GlaxoSmithKline licenses Amicus drug in $230M deal
GlaxoSmithKline licenses Amicus drug in $230M deal
Bizjournals.com
Amicus Therapeutics
GSK
licensing
Amigal
Fabry's disease
Flag link: